Profile data is unavailable for this security.
About the company
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
- Revenue in DKK (TTM)188.29bn
- Net income in DKK61.13bn
- Incorporated1931
- Employees57.09k
- LocationNovo Nordisk A/SNovo Alle 1BAGSVAERD 2880DenmarkDNK
- Phone+45 44448888
- Fax+45 44436633
- Websitehttps://www.novonordisk.com/
Mergers & acquisitions
| Acquired company | NOVO B:CPH since announced | Transaction value |
|---|---|---|
| Forma Therapeutics Holdings Inc | 40.85% | 1.11bn |
| Marinus Pharmaceuticals Inc-Priority Review Voucher | 37.77% | 110.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer AG | 376.03bn | 22.62bn | 390.86bn | 101.74k | 17.28 | 1.28 | 5.50 | 1.04 | 3.09 | 3.09 | 51.39 | 41.60 | 0.4026 | 1.67 | 3.46 | 498,071.40 | 2.44 | -1.11 | 3.30 | -1.45 | 59.54 | 58.98 | 6.05 | -3.04 | 0.7587 | 4.95 | 0.5135 | -- | 15.10 | 7.70 | 315.00 | 5.02 | 4.50 | -2.72 |
| GSK plc | 250.50bn | 37.38bn | 483.53bn | 69.40k | 12.44 | 4.75 | 8.00 | 1.93 | 1.10 | 3.64 | 7.52 | 2.89 | 0.3923 | 1.51 | 3.84 | 419,092.20 | 6.45 | 6.39 | 9.82 | 10.42 | 70.42 | 69.55 | 16.44 | 15.90 | 0.694 | 9.71 | 0.6489 | 93.37 | 18.74 | -0.5778 | 51.73 | 10.27 | 0.5035 | -5.53 |
| Sanofi SA | 344.08bn | 62.24bn | 886.68bn | 91.57k | 14.19 | -- | 11.32 | 2.58 | 6.65 | 6.65 | 36.84 | -- | -- | -- | -- | 504,504.60 | -- | 5.80 | -- | 7.02 | 69.93 | 68.49 | 18.24 | 17.00 | -- | 102.64 | -- | 59.84 | 15.86 | 4.62 | 34.52 | 17.28 | 2.39 | 3.28 |
| Novartis AG | 361.61bn | 48.73bn | 1.52tn | 103.00k | 29.63 | 3.88 | 17.37 | 4.20 | 2.94 | 2.94 | 21.78 | 22.48 | 0.4391 | 2.03 | 6.02 | 464,186.40 | 5.92 | 9.09 | 7.95 | 11.77 | 71.09 | 70.98 | 13.48 | 23.68 | 0.7931 | 12.26 | 0.3586 | 59.94 | -2.15 | 3.60 | -71.05 | -1.49 | 3.09 | 3.79 |
| AstraZeneca plc | 304.17bn | 32.64bn | 1.53tn | 83.50k | 47.09 | 6.15 | 21.20 | 5.02 | 2.43 | 2.43 | 22.64 | 18.60 | 0.4452 | 1.35 | 4.62 | 422,959.70 | 4.78 | 2.63 | 6.31 | 3.62 | 80.63 | 78.99 | 10.74 | 6.35 | 0.6959 | 6.82 | 0.468 | 187.07 | 18.53 | 14.57 | 2,835.71 | 6.63 | 9.68 | 1.13 |
| Roche Holding AG | 484.71bn | 95.14bn | 1.80tn | 103.61k | 18.75 | 8.22 | 13.56 | 3.72 | 15.36 | 15.36 | 78.32 | 35.03 | 0.7013 | 2.27 | 5.65 | 610,743.80 | 15.00 | 16.21 | 25.31 | 25.33 | 70.75 | 71.07 | 21.38 | 22.62 | 0.9256 | 19.25 | 0.4419 | 59.33 | 0.7643 | 3.49 | -10.83 | 7.26 | 2.63 | 2.74 |
| Novo Nordisk A/S | 188.29bn | 61.13bn | 1.92tn | 57.09k | 41.52 | 31.42 | 28.29 | 10.18 | 26.88 | 26.88 | 82.71 | 35.52 | 0.8422 | 1.29 | 4.34 | 3,461,659.00 | 27.34 | 29.83 | 55.67 | 58.58 | 84.22 | 83.76 | 32.47 | 32.86 | 0.6694 | 16.84 | 0.2421 | 45.88 | 25.68 | 9.64 | 16.27 | 7.81 | 11.27 | 9.57 |
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 04 May 2023 | 66.35m | 3.86% |
| The Vanguard Group, Inc.as of 05 May 2023 | 43.49m | 2.53% |
| Norges Bank Investment Managementas of 31 Dec 2022 | 43.41m | 2.53% |
| BlackRock Fund Advisorsas of 04 May 2023 | 28.86m | 1.68% |
| Alecta Pension Insurance Mutualas of 31 Dec 2019 | 27.09m | 1.58% |
| Fundsmith LLPas of 30 Jun 2022 | 21.22m | 1.24% |
| Capital Research & Management Co. (Global Investors)as of 04 May 2023 | 18.31m | 1.07% |
| BlackRock Investment Management (UK) Ltd.as of 30 Apr 2023 | 16.77m | 0.98% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2023 | 13.38m | 0.78% |
| BlackRock Advisors (UK) Ltd.as of 04 May 2023 | 12.57m | 0.73% |
